Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies

Human Antibodies

Volumn 20, Issue 3-4, 2011, Pages 95-101

  Kaja, Simon ^a   Hilgenberg, Jill D ^a   Everett, Eric ^b   Olitsky, Scott E ^a,c   Gossage, Jim ^c,d   Koulen, Peter ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b O'Brien Pharmacy   (United States)

^c HHT Foundation International   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Avastin ; bevacizumab; dilution; Hereditary hemorrhagic telangiectasia; storage

Indexed keywords

BENZALKONIUM CHLORIDE; BEVACIZUMAB; NOSE SPRAY; POLYETHYLENE;

ARTICLE; CHEMICAL ANALYSIS; DILUTION; DRUG INDICATION; DRUG STABILITY; DRUG STORAGE; ELECTROCHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZING; HUMAN; ISOELECTRIC FOCUSING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE;

ACTIVIN RECEPTORS, TYPE II; ADMINISTRATION, INTRANASAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZALKONIUM COMPOUNDS; DRUG STABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; HUMANS; ISOELECTRIC FOCUSING; NASAL SPRAYS; POLYETHYLENE; PRESERVATIVES, PHARMACEUTICAL; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82555170648     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-2011-0244     Document Type: Article

References (17)

1. C.L. Shovlin, Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment, Blood Rev 24 (2010), 203-219.
2. M.S. Pepper, S.J. Mandriota, J.D. Vassalli, L. Orci and R. Montesano, Angiogenesis-regulating cytokines: activities and interactions, Curr Top Microbiol Immunol 213(Pt 2) (1996), 31-67. (Pubitemid 26167912)
3. A.Dimberg, Chemokines in angiogenesis, Curr TopMicrobiol Immunol 341 (2010), 59-80.
4. H. Sadick, F. Riedel, R. Naim, U. Goessler, K. Hormann, M. Hafner and A. Lux, Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression, Haematologica 90 (2005), 818-828.
5. A. Mitchell, L.A. Adams, G. MacQuillan, J. Tibballs, R. vanden Driesen and L. Delriviere, Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia, Liver Transpl 14 (2008), 210-213. (Pubitemid 351267278)
6. S. Patrizia, L. Arcangelo and S. Carlo, Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia, Br J Haematol 152 (2011), 365.
7. D. Flieger, S. Hainke and W. Fischbach, Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab, Ann Hematol 85 (2006), 631-632. (Pubitemid 44283088)
8. T.M. Davidson, S.E. Olitsky and J.L.Wei, Hereditary hemorrhagic telangiectasia/avastin, Laryngoscope 120 (2010), 432-435.
9. S.t. Chen, T. Karnezis and T.M. Davidson, Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis, Laryngoscope 121 (2011), 644-646.
10. T.T. Karnezis and T.M. Davidson, Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis, Laryngoscope 121 (2011), 636-638.
11. T. Arakawa, J.S. Philo andY.Kita, Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietin, Biosci Biotechnol Biochem 65 (2001), 1321-1327. (Pubitemid 33617386)
12. S. Fasler, F. Skvaril and H.U. Lutz, Electrophoretic properties of human IgG and its subclasses on sodium dodecyl-sulfatepolyacrylamide gel electrophoresis and immunoblots, Anal Biochem 174 (1988), 593-600.
13. A. Klettner and J. Roider, Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways, Invest Ophthalmol Vis Sci 49 (2008), 4523-4527.
14. T.U. Krohne, N. Eter, F.G. Holz and C.H. Meyer, Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans, Am J Ophthalmol 146 (2008), 508-512.
15. M. Vlckova, F. Kalman and M.A. Schwarz, Pharmaceutical applications of isoelectric focusing on microchip with imaged UV detection, J Chromatogr A 1181 (2008), 145-152.
16. L. Liu, D.A. Ammar, L.A. Ross, N. Mandava, M.Y. Kahook and J.F. Carpenter, Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and ProductMishandling, Invest Ophthalmol Vis Sci 52 (2011), 1023-1034.
17. B. Marple, P. Roland and M. Benninger, Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions, Otolaryngol Head Neck Surg 130 (2004), 131-141. (Pubitemid 38113927)